Size : 1mg
Telefonnummer : +1 850 650 7790
Synonyms:
| Description | OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines. |
| Targets & IC50 | OGT:60 nM, OGT:3 μM (EC50) |
| In vitro | Method: HEK293T cells were treated with OSMI-4 (10 μM, 2 hours) and quantitative PCR was performed using primers for the OGT retained intron (intron 4) and spliced exon (exon 4). Result The bar graph shows that OSMI-4 increases retained intron splicing. [1] Method: HEK293T cells were treated with OSMI-4 (20, 50 μM, 24 hours); HEK293T cells were treated with OSMI-4 (0.1, 1, 5, 5, 10, 20 μM, 2, 24, 48 hours); Western blot analysis of total O-GlcNAc was performed. Result O-GlcNAc levels were reduced to a greater extent following OSMI-4 treatment; 24 hours of OSMI-4 treatment of HEK293T cells resulted in a dose-dependent decrease in O-GlcNAc levels, with effects seen with only 5 µM of compound treatment, and these effects could be observed in as little as 2 hours or 48 hours. [1] |
| Molecular Weight | 604.09 |
| Formula | C27H26ClN3O7S2 |
| Cas No. | 2260791-14-6 |
| Smiles | CCOC(=O)CN(Cc1cccs1)C(=O)[C@H](NS(=O)(=O)c1cc2ccc(=O)[nH]c2cc1Cl)c1ccccc1OC |
| Relative Density. | 1.414 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 252.5 mg/mL (417.98 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 10 mg/mL (16.55 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
